Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $2.75
Previous CloseN/A
Volume293.07K
Average Volume (3M)96.40K
Market Cap
$54.90M
Enterprise Value-$21.04K
Total Cash (Recent Filing)$35.50M
Total Debt (Recent Filing)$55.08K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 07, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding89,704,190
10 Day Avg. Volume96,445
30 Day Avg. Volume96,401
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio11.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.50Price Target Upside561.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Context Therapeutics News
PremiumCompany Announcements
Context Therapeutics: 2024 Financial and Strategic Highlights
PremiumCompany Announcements
Context Therapeutics Advances CTIM-76 in Clinical Pipeline
PremiumCompany Announcements
Context Therapeutics Appoints Andy Pasternak as Chairman---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsContext Therapeutics is on track to start clinical trials for its CTIM-76, CT-95, and CT-202 assets, indicating progress in their development pipeline.
Financial StrengthCNTX raised $100M in a private placement, resulting in a year-end cash balance of $94.4M, which is expected to support operations into 2027.
Research And DevelopmentCTIM-76 demonstrated high potency and target selectivity in both binding and cytotoxicity assays, showcasing its potential in targeting CLDN6 while avoiding CLDN9.
Bears Say
Market ConditionsBroad market headwinds continue including challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.
ValuationValuations across much of the biotech space have continued to pullback and reset, leading to an increased discount rate in the valuation model for Context.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.55 and its highest was $2.75 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $54.90M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 34 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.092 by $0.062.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 89,704,190 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.092. Following the earnings report the stock price went down -6.098%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
---
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (561.76% Upside)
$4.50 (561.76% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 668.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 22.2%
Last 30 Days ▲ 22.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.78%
12-Months-Change
Fundamentals
Return on Equity
-49.89%
Trailing 12-Months
Asset Growth
510.90%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hormone-driven cancers. The company operates in the biotechnology and healthcare sectors, with a core emphasis on advancing therapies for breast, ovarian, and endometrial cancers. Context Therapeutics is dedicated to improving patient outcomes by targeting hormone receptors and pathways that are pivotal in cancer progression.
---
CNTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(561.76% Upside)
Technical Analysis
Best Analysts Covering CNTX
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-16.04%
reiterated a buy rating 14 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -16.04% per trade.
---